BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25069847)

  • 1. [Pleural mesothelioma. Cytology and molecular diagnostics].
    Vlajnic T; Savic S; Bubendorf L
    Pathologe; 2014 Nov; 35(6):591-6. PubMed ID: 25069847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphological diagnostics of malignant pleural mesothelioma].
    Junker K; Müller KM
    Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
    Cagle PT; Churg A
    Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
    Hiroshima K; Wu D; Hasegawa M; Koh E; Sekine Y; Ozaki D; Yusa T; Walts AE; Marchevsky AM; Nabeshima K; Tada Y; Shimada H; Tagawa M
    Diagn Cytopathol; 2016 Jul; 44(7):591-8. PubMed ID: 27079839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
    Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
    Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
    Matsumoto S; Hamasaki M; Kinoshita Y; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2019 Nov; 69(11):637-645. PubMed ID: 31580004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
    Nabeshima K; Matsumoto S; Hamasaki M; Hida T; Kamei T; Hiroshima K; Tsujimura T; Kawahara K
    Diagn Cytopathol; 2016 Sep; 44(9):774-80. PubMed ID: 27219841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
    Shin HJ; Shin DM; Tarco E; Sneige N
    Cancer; 2003 Aug; 99(4):233-9. PubMed ID: 12925985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
    Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
    Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
    Paintal A; Raparia K; Zakowski MF; Nayar R
    Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
    Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
    Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
    Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.
    Tsao MS; Carbone M; Galateau-Salle F; Moreira AL; Nicholson AG; Roden AC; Adjei AA; Aubry MC; Fennell DA; Gomez D; Harpole D; Hesdorffer M; Hirsch FR; Liu G; Malik S; Nowak A; Peikert T; Salgia R; Szlosarek P; Taioli E; Yang H; Tsao A; Mansfield AS
    J Thorac Oncol; 2019 Oct; 14(10):1704-1717. PubMed ID: 31260832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological and molecular biological approaches to early mesothelioma.
    Tsujimura T; Torii I; Sato A; Song M; Fukuoka K; Hasegawa S; Nakano T
    Int J Clin Oncol; 2012 Feb; 17(1):40-7. PubMed ID: 22237727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.